NCT03708900
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
Recruiting
PHASE2Ages 2–17InterventionalTreatmentRECORDATI GROUP
~12 participants
Updated 2026-03-27 on ClinicalTrials.gov
What's tested:LCI699
At a glance
Recruiting sites
4 of 15 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Core Study: Evaluate the pharmacokinetics (PK) of osilodrostat using Pharmacokinetic parameters of osilodrostat up to Week 12 in children and adolescents 2 to less than 18 years of age with Cushing's Syndrome
Measured over up to Week 12
Conditions
Where it's being run
15 sites across 12 statesFrance3
United Kingdom2
California1
Florida1
Illinois1
Maryland1
Texas1
Brussels Capital1
Study leadership
- Recordati AG · STUDY_DIRECTOR · Recordati AG
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Core Study: Evaluate the pharmacokinetics (PK) of osilodrostat using Pharmacokinetic parameters of osilodrostat up to Week 12 in children and adolescents 2 to less than 18 years of age with Cushing's Syndromeup to Week 12
evaluate the pharmacokinetics (PK) of osilodrostat in children and adolescents of 2 to less than 18 years of age with Cushing's Syndrome